Home/Pipeline/PRIMA Retinal Implant

PRIMA Retinal Implant

Geographic Atrophy secondary to Age-Related Macular Degeneration (Vision Restoration)

Phase 2/3Active

Key Facts

Indication
Geographic Atrophy secondary to Age-Related Macular Degeneration (Vision Restoration)
Phase
Phase 2/3
Status
Active
Company

About Science

Science Corporation is a private, clinical-stage medical technology firm pioneering biohybrid neural interfaces and brain-computer interface (BCI) systems. Its flagship technology is the PRIMA retinal implant, a subretinal microphotodiode array designed to restore vision in patients blinded by advanced geographic atrophy due to age-related macular degeneration, with breakthrough results published in The New England Journal of Medicine. The company is vertically integrated, developing the full technology stack from neural recording electronics to laser projection optics, and recently secured a $230 million Series C financing round to fund commercialization of PRIMA and expand clinical trials. Beyond vision restoration, Science is exploring a broader BCI ecosystem through partnerships and its 'Vessel' perfusion technology platform.

View full company profile

Therapeutic Areas